Product Information
ISOTRETINOIN 30 MG CAPSULE is a generic product labeled by Actavis Pharma, Inc., priced at $4.4724 per EA under NDC 00591243515. Its NADAC has been published 246 times since May 19, 2021.
FDA first approved this application on Mar 31, 2021. Its Orange Book therapeutic-equivalence code is AB2 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
30 mg/1
Manufacturer
Actavis Pharma, Inc.NDC
00591243515
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ISOTRETINOINApproval Type
Generic (ANDA)
FDA Application
ANDA205063FDA Approved
3/31/2021
TE Code
AB2
On Market Since
4/29/2021
Pharmacological Classes
Price Statistics
The NADAC for ISOTRETINOIN 30 MG CAPSULE has been published 246 times since May 19, 2021, and over the history we have for it it has risen 20.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $4.4724 per EA |
|---|---|
| All-time high | $26.6923 (Jun 15, 2022) |
| All-time low | $3.5783 (Jun 23, 2021) |
| 52-week high | $10.7129 |
| 52-week low | $3.6838 |
| Median price | $15.3207 |
| Average price | $15.1539 |
| Largest weekly change | +646.0% (Jul 21, 2021) |
| Weeks tracked | 246 |
| Tracking since | May 19, 2021 |
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 52% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Actavis Pharma, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Isotretinoin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Retinoid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ISOTRETINOIN 30 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for ISOTRETINOIN 30 MG CAPSULE, manufactured by Actavis Pharma, Inc., is $4.4724 per EA (NDC 00591243515), effective Sep 30, 2026.
How has the price of ISOTRETINOIN 30 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for ISOTRETINOIN 30 MG CAPSULE has risen 20.6%. It has been tracked across 246 weekly CMS publications since May 19, 2021.
What are the highest and lowest recorded NADAC prices for ISOTRETINOIN 30 MG CAPSULE?
Since May 19, 2021, the NADAC for ISOTRETINOIN 30 MG CAPSULE has ranged from a low of $3.5783 (Jun 23, 2021) to a high of $26.6923 (Jun 15, 2022), with a median of $15.3207 per EA.
Are there cheaper alternatives to ISOTRETINOIN 30 MG CAPSULE?
Yes. 6 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ISOTRETINOIN 30 MG CAPSULE, is $2.1254 per EA — about 52% below ISOTRETINOIN 30 MG CAPSULE.
Who manufactures ISOTRETINOIN 30 MG CAPSULE?
ISOTRETINOIN 30 MG CAPSULE (NDC 00591243515) is labeled by Actavis Pharma, Inc., and CMS classifies it as a generic product.